Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2020-06-05 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Impact of COVID-19
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements), 2015. It discusses the impact of COVID-19 on the company's operations, including production capacity, supply chain interruptions, order deferrals, liquidity issues, and partial office closures. The document is short (1792 characters) and serves as a disclosure or update rather than a detailed financial report or presentation. It does not contain financial statements, audit information, or detailed management analysis. It is a regulatory disclosure about operational impact due to COVID-19, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure.
2020-06-05 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notification from the company to stock exchanges about an upcoming Board Meeting scheduled to consider the adoption of Audited Standalone and Consolidated Financial Results for the fiscal year ended 31st March 2020. It is an announcement of a meeting date and agenda, not the financial results report itself. The document length is short (1390 characters) and it does not contain any financial data or detailed results. Therefore, it is not an Annual Report (10-K) or an Earnings Release (ER). It is also not a certification or regulatory filing. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing the market about the board meeting and the timing of financial results consideration, which does not fit other specific categories.
2020-06-03 English
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/06/2020 ,inter alia, to consider and approve With respect to above we wish to ....
Regulatory Filings Classification · 95% confidence The document is a notification from the company to stock exchanges about an upcoming Board Meeting scheduled for June 10, 2020, to consider the audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2020. It does not contain the financial results themselves but informs about the meeting where these results will be adopted. The document is short (1408 characters) and serves as an announcement rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about the board meeting and financial results consideration, not the actual financial report or earnings release.
2020-06-03 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2020-05-22 English
As required under Regulation 40(9) of SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, we enclose herewith a copy of Compliance Certificate dated 23rd April, 2020 ....
Regulatory Filings
2020-04-23 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 31st March 2020. It is a compliance certificate related to dematerialization of securities and submission of details to stock exchanges. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory compliance certificate rather than a financial report or announcement of a report. The document length is 2662 characters, which is relatively short and consistent with a certification letter. Therefore, according to the Certification Rule, this document should be classified as a Regulatory Filing (RNS).
2020-04-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.